34 results about "Cortical neuron" patented technology

A Switching Kalman Filter Model for the real-time inference of hand kinematics from a population of motor cortical neurons. Firing rates are modeled as a Gaussian mixture where the mean of each Gaussian component is a linear function of hand kinematics. A “hidden state” models the probability of each mixture component and evolves over time in a Markov chain. Gaussian mixture models and Expectation Maximization (EM) techniques are extended for automatic spike sorting. Good initialization of EM is achieved via spectral clustering. To account for noise, the mixture model is extended to include a uniform outlier process. A greedy optimization algorithm that selects models with different numbers of neurons according to their decoding accuracy is used to automatically determine the number of neurons recorded per electrode. Closed loop neural control of external events are demonstrated using neural control of a computer curser.

A nanostructured molecular delivery vehicle comprising magnetic materials and configured to receive passenger biomolecules. The application of a an appropriate magnetic field having a gradient orients and drives the vehicle into a biological target, which may comprise cells, cell masses, tissue slices, tissues, etc. Under the control of the magnetic field, these vehicles can penetrate cell membranes. Then, the biomolecules carried by the vehicle can be released into the cells to perform their functions. Using this “nanospearing” technique, unprecendented high transfection efficiency has been achieved in several difficult-to-transfect cells. These include, but are not limited to, Bal 17 cells, ex vivo B cells, primary cultured cortical neurons, etc. This method advances the state of the art, providing an improved technique for the introduction of exogenous molecules to cells, with the clinical applications including, but not being limited to, drug delivery, gene therapy, vaccination, etc.

The invention discloses application of artemisinin and derivatives thereof in preparing medicaments for preventing and treating neurological diseases. In the application, the nerve cell line of rat adrenal pheochromocytoma PC12, retinal nerve cell line RGC-5 and primary cortical neuron are on behalf of experiment objects, sodium nitroprusside and hydrogen peroxide are used to simulate and induce oxidative stress, cell apoptosis and other cell injuries of nerve cells. Researches discover that the artemisinin has a protective effect on sodium nitroprusside and hydrogen peroxide induced cell injury, the protective effect mechanism of the artemisinin and derivatives thereof is primarily discussed, and results indicate that the artemisinin and derivatives thereof can be used as nerve protection medicaments for preventing and treating various neurological diseases, such as various neurodegenerative diseases, acute and chronic neurodegenerative diseases, neurological eye disease and the those neurological diseases mainly related to oxidative stress injuries and cell apoptosis. The application brings a new direction to treatment and prevention of neurological diseases.

The invention discloses new pharmaceutical uses of 7, 4'- di(mono succinate) oxyethoxypropyl daidzein. Pharmacological activity research is carried out to DZ5 by an experimental model for mice under atmospheric hypoxia tolerance, an experimental model for mice acute cerebral ischemia, an experimental model for bilateral common carotid arteries and vagus nerve ligation, an experimental model for mice KCN poisoning, an experimental model for mice NaNO2 poisoning and experimental model for learning and remembering, an action model for rat cortical neuron damage caused by anoxia of DZ5, an effect model for rat myocardial ischemia caused by hypophysin, an experimental model for vitro anti platelet aggregation, an experimental model for vivo anti platelet aggregation, and an effect model for arterial thrombosis in rabbits. Proved by the result, DZ5 has the functions of anti-cerebral ischemia and anoxia, anti-myocardial ischemia and anoxia, antagonistic memory disorders, anti-platelet aggregation and thrombosis, and protection of rat cortical neuron damage caused by anoxia. DZ5 can be mixed with a pharmacologically acceptable carrier or excipient to prepare medicine compositions.

The invention relates to a neuron in-vitro culture method for synaptic plasticity research on a visual cortex neuron. The method is characterized by comprising the following steps: (1) carrying out pretreatment on cerebral tissues of fetal rats, separating visual cortex tissues and carrying out proteinase digestion and centrifugation; (2) adding an inoculation medium to terminate digestion; (3) blowing a single-cell suspension, sieving and counting; and (4) inoculating with the inoculation medium of which the density is 2.5*10<4> / cm<2> to 5*10<4> / cm<2>, carrying out adherent culture in a full liquid-exchange manner, and after cell attachment, carrying out subsequent culture in a half liquid-exchange manner. The invention further provides a visual cortex neuron cell line of rats, which is cultured by the neuron in-vitro culture method, and an application of the visual cortex neuron cell line in synaptic plasticity research on the visual cortex neuron. The culture method is efficient and simple; the neuron is high in purity, and good in state, and has a structural basis of neuronal synaptic plasticity; the functional state of the neuronal synaptic plasticity can be reflected; and the culture method can be applied to research on the synaptic plasticity of visual cortex of rats.

The invention provides application of mesenchymal stem cell derived extracellular vesicles to cerebral ischemia-reperfusion injury. Research of the invention finds and verifies that extracellular vesicles (MSCs-EVs) derived from mesenchymal stem cells are capable of treating disordered brain functions and taking a neuroprotective effect into play through neurogenesis and angiogenesis after stroke.Research results show that within 24 hours and 48 hours after MCAO (middle cerebral artery occlusion), MSCs-EVs are capable of remarkably reliving neurologic impairment of rats, reducing the volume of cerebral infarction and brain water contents, relieving pathological injury of brain tissue cortexes, weakening cortex neuronal apoptosis, remarkably increasing p-AMPK (protein kinase), and reducingp-JAK2, p-STAT3 and p-NF-kB. Due to the application, essential support is provided for potential treatment strategies of MSCs-EVs as MCAO treatment.

A nanostructured molecular delivery vehicle comprising magnetic materials and configured to receive passenger biomolecules. The application of a an appropriate magnetic field having a gradient orients and drives the vehicle into a biological target, which may comprise cells, cell masses, tissue slices, tissues, etc. Under the control of the magnetic field, these vehicles can penetrate cell membranes. Then, the biomolecules carried by the vehicle can be released into the cells to perform their functions. Using this “nanospearing” technique, unprecendented high transfection efficiency has been achieved in several difficult-to-transfect cells. These include, but are not limited to, Bal 17 cells, ex vivo B cells, primary cultured cortical neurons, etc. This method advances the state of the art, providing an improved technique for the introduction of exogenous molecules to cells, with the clinical applications including, but not being limited to, drug delivery, gene therapy, vaccination, etc.

The invention discloses applications of dendrobium nobile lindl alkaloids (DNLA) in medicines prepared for treating ischemic brain damage and a product thereof. The DNLA is lipophilic total alkaloids composition which is extracted from the dendrobium nobile lindl. Compared with the prior art, the invention aims at the nosogenesis of stroke, studies the protection function of the DNLA on oxygen-glucose deprivation injury model of primary cortical neurons and acute cerebral ischemia model of rats, analyzes the mechanism, further makes clear the pharmacological action and mechanism action of the DNLA for treating cerebral ischemia, and provides pharmacological basis for the development and applications of the dendrobium nobile lindl medical material.

The invention belongs to the technical field of image feature extraction and target recognition. The invention discloses an image feature extraction and target recognition method and system, a storagemedium and a terminal, the method comprises the steps of: establishing a computer model suitable for human primary visual cortex neuronal cells, establishing a recognition response mechanism of a visual abdominal side system, and performing image feature extraction, sample training and object recognition on the visual abdominal side system. Results show that compared with a traditional method, the method effectively improves the recognition of the image features, and the image features extracted in a complex background scene have good generalization ability. On the basis, the training samplecan be effectively identified. Results show that recognition of the edge, direction and contour of a training sample based on a model of a visual neural mechanism shows the advantages of a biologicalvisual mechanism in the aspect of object recognition.

The invention relates to magnolia odoratissma alkyl diol which promotes regeneration of a nerve cell system and nerve cell axons, can promote increase of low-concentration induced PC-12 cell differentiation amount, obvious increased of the cell axon amount, obvious increase of axon length, obvious increase of neuroma mother cell N1E-115 axon length and prolonging and regeneration of fetal rat primary cortical neuron axons.

The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and Aβ-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two.

The invention discloses benzotetrazole derivatives. The benzotetrazole derivatives have a structure represented by a general formula I or a general formula I'. In the general formula I or the generalformula I', R1 is a C3-C5 alkyl chain or a halogenated alkyl chain, R2 is one or a plurality of elements selected from H, Cl, F and Br or a combination of two or a plurality of elements selected fromH, Cl, F and Br, R3 is H, F or CH3, and R4 is a C1-C2 alkyl chain. The invention also discloses optical isomers of the derivatives, or pharmaceutically acceptable salts or solvates of the derivatives,or pharmaceutically acceptable salts or solvates of the optical isomers. The invention further discloses compositions containing the benzotetrazole derivatives and application of the compositions inpreparation of medicines for preventing and resisting cerebral apoplexy. Repeated experiments prove that the derivatives provided by the invention shows strong protective activity on OGD / R molded mouse primary cortical neuronal cells. Therefore, the derivatives disclosed by the invention can be applied as neuroprotective agents to medicines for treating and preventing cerebral apoplexy.

Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in excitatory cortical neurons, such as primarily within cortical layers 2 / 3, 4, 5, and 6 and including those with extratelencephalic (ET) projections, intratelencephalic (IT) projections, and pyramidal tract (PT) projections, among others.

The invention discloses a three-dimensional combined micro-channel for inducing orientated growth of primary cortical neuron axons. The three-dimensional combined micro-channel comprises a soft photoetching supporting channel and a two-photon photoetching axon growth bracket, a first interaction interface and a second interaction interface are formed in the soft lithography supporting flow channel, and a first cell chamber and a second cell chamber are arranged in the soft lithography supporting flow channel; the first cell chamber is communicated with the first interaction interface, and the second cell chamber is communicated with the second interaction interface; the two-photon photoetching axon growth support is embedded in the soft photoetching supporting flow channel, the two-photon photoetching axon growth support comprises a growth cavity penetrating through the two-photon photoetching axon growth support, the first end of the growth cavity is communicated with the first interaction interface, and the second end of the growth cavity is communicated with the second interaction interface; the growth cavity comprises at least one ascending section, and the ascending section is formed by changing the growth cavity in the Z-axis direction. The problem that three-dimensional directional growth of nerve axons under the directional flowing condition is difficult to achieve through a flow channel in the prior art is solved.

The invention discloses application of cholest-3,6-dione, deuterated substances thereof or pharmaceutically acceptable salts thereof to preparation of drugs used for treating the neuronal damage of patients. According to the invention, it is proved that cholest-3,6-dione can alleviate the oxidative stress damage of hippocampal neurons induced by glutamate, mitigate the apoptosis of cerebellar granule neurons caused by potassium deprivation, and abate the neuroexcitotoxic injury of cortical neurons induced by glutamate, so cholest-3,6-dione can be applied to treatment of neuronal damage.

The invention discloses a tetrazole derivative with a structure as shown in a general formula I. The invention also discloses a composition containing the tetrazole derivative and application of the composition in preparation of drugs for preventing and resisting cerebral apoplexy. Through multiple experiments, the inventor of the invention proves that the compound has an obvious inhibition effect on ADP-induced platelet aggregation activity, and has an outstanding damage protection effect on neuron-like cells induced and differentiated by OGD / R fetal mouse primary cortical neuronal cells and neuroblastoma cells (N2A); for a focal cerebral ischemia animal model constructed by transient middle cerebral artery occlusion through a suture method, the compound has a good anti-cerebral apoplexy drug effect and good rat oral pharmacokinetic property. Therefore, the compound disclosed by the invention can be used as a neuroprotective agent to be applied to medicines for treating and preventing cerebral apoplexy.

The invention relates to a contour detection method based on the synergistic effect of multi-level inhibition zones of visual pathways. The present invention first constructs a direction-sensitive outer geniculate neuron array, records the contour direction selected by the outer geniculate body, and calculates the response of the outer geniculate neuron; takes the distance as a factor for the visual input of the classic receptive field and inhibitory area of ​​the outer geniculate neuron Carry out quantitative processing, take the difference between the two as the effective response of the inhibition area, and obtain the synergy parameters through dynamic rectification and power exponent normalization; obtain the visual input of the primary visual cortex through the local window weighted fusion of the response of the outer geniculate neurons, and detect Accurate contour response; calculate the primary visual cortex neuron inhibitory area response to obtain the final contour response. The invention considers the step-by-step refined detection mechanism when neurons at different levels perceive directions in the visual pathway, and simultaneously simulates the synergistic effect of inhibition areas between different levels, which can effectively improve the contour detection performance of natural images.

The invention relates to a method for producing hiPSCs derived brain-like tissue. The method comprises the following steps of (1) preparing a microcolumn array chip; and (2) inducing the brain-like tissue on the chip. Brain-like organs produced by the method have relevant characteristics of in vivo brain development on gene level and protein level. The method is simple, a tedious matrigel packaging step is removed, matrigel consumption is reduced, and only additional Dorsomorphine and A83-01 need to be added at the stage of forming an embryoid body. The brain-like organs induced to 30 days have expression of cortex nerve cells (TBR1 and CTIP2), expression of mature nerve cells (TUJ1), expression of front brain (PAX6 and FOXG1) and expression of afterbrain protein (PAX2 and ISL-1), and haveexpression of excitatory neuron (vGLUT1) subtypes and inhibitory neurons (GABA) subtypes.

The invention provides a Chinese medicinal composition for treating ischemia apoplexy, which is prepared from raw rehmannia, dendrobe, raw astragalus mongholicus, kudzuvine root, leech, hemlock parsley, earthworm, morinda officinalis and scutellaria baicalensis. The Chinese medicinal composition has the functions of remarkably reducing vascular permeability, reducing the symptom of neurologic impairment, reducing occurrence of cerebral infarction, reducing the total volume of infarction, infarction of cortex and infarction under cortex to varying degrees, and remarkably improving the survival rate of cortical neuron, and has good curative effect to ischemia apoplexy.

The invention provides miR-25-3p as well as application and an application method thereof, and relates to the technical field of biomedicine, the miR-25-3p is used as a molecular intervention target, and overexpresses the miR-25-3p so as to promote growth of DGR neuron and cortical neuron axons. The miR-25-3p participates in peripheral nerve injury repair by adjusting the growth of DGR neuron axons. The miR-25-3p participates in central nervous system injury repair by adjusting cortical neuron axon growth. According to the invention, firstly, a small RNA, that is, miR-25-3p is found through screening, and is found can play an important role in nerve injury repair. The miR-25-3p mimic is transfected in the in-vitro DRG neuron, so that the growth of the DRG neuron subjected to primary culture and cortical neuron axons can be obviously promoted. The miR-25-3p can participate in peripheral nerve injury repair by adjusting DRG neuron axon growth, and can also participate in central nerve injury repair by adjusting cortical neuron axon growth. The important effect of miRNA in the nerve injury repair process can be better understood, and a new target spot is provided for treatment after nerve injury.

The invention belongs to the technical field of life science / medicine, and discloses a perception training device for auditory cortex plasticity based on painless training stimulation. The training device is located in a sound insulation shielding box, and comprises a controller, a sound generator, a loudspeaker, a feeding device, an infrared nose detector and an illuminating lamp. The invention further discloses application of the training device in induction and perception training of the auditory cortex plasticity. The device has the characteristics of non-invasion, broad spectrum and the like, improves the frequency selectivity of auditory cortex neurons, and has a wide application prospect.

The present invention relates to the effect of Radix Pseudostellariae water extract, Radix Pseudostellariae cyclic peptide extract, and Radix Pseudostellariae cyclic peptide B on memory enhancement in normal mice and the improvement of learning and memory impairment in dementia mice induced by Aβ1-42 injection into the contralateral ventricle, and explores the mechanism of action thereof. The results clearly indicate that Radix Pseudostellariae water extract, Radix Pseudostellariae cyclic peptide extract, and Radix Pseudostellariae cyclic peptide B can significantly enhance the cognitive and memory ability of normal mice and improve the memory impairment of dementia model mice, promote the regeneration of neuronal processes in the cerebral cortex, and protect against the loss and protrusion atrophy of cortical neurons induced by Aβ; the results suggest that Radix Pseudostellariae cyclic peptide B and Radix Pseudostellariae water and cyclic peptide extracts may improve memory by promoting the regeneration of nerve processes and rebuilding the neural circuit network, and can be used for preparing medicines or health foods for preventing and treating Alzheimer's disease.

The invention belongs to fields of gene functions and application. Neuron-specific IRF 6 knock-out mice and neuron-specific IRF 6 transgenic mice serve as experimental subjects, and a brain stroke model caused by middle cerebral artery ischemic reperfusion injury is researched, so results indicate that compared with wild mice, the IRF 6 gene knock-out mice have the characteristics that the infarct volume is remarkably reduced, the nerve function is remarkably improved, and the number of dead nerve cells is reduced; and IRF 6 gene overexpressed mice have the characteristics that the infarct volume is remarkably increased, the nerve function is remarkably deteriorated and the number of dead nerve cells is increased. In vitro cell experiments indicate that adenovirus-mediated IRF 6 interference can protect an injury of primary cortical neurons caused by anoxia / reoxygenation and inhibit neuron apoptosis. Therefore, the IRF 6 has the effect of deteriorating the nerve function, and can aggravate and promote development of brain stroke, and theoretical basis and clinical base are provided for researching a new target spot and a new strategy for preventing, relieving and / or treating the brain stroke disease.

The invention belongs to the field of functions and application of genes. An IRF5 (Interferon Regulatory Factor 5) gene knockout mouse is used as an experiment object; a mouse middle cerebral artery ischemia and reperfusion injury caused cerebral stroke model is researched; a result shows that compared with a control group mouse, the infarct volume of the IRF5 gene knockout mouse is obviously reduced, a neurologic function is obviously improved and the quantity of dead nerve cells is reduced; the infarct volume of an IRF5 gene overexpression mouse is obviously improved, the neurologic function is obviously worsened and the quantity of the dead nerve cells is increased. An in vitro cell experiment shows that oxygen-poor / oxygen restoration injuries of primary cortical neuron cells can be inhibited through adenovirus vector mediated DEC1 (Deleted in Esophageal Cancer 1) interference and neuron cell apoptosis is inhibited. Therefore, an IRF5 has an effect of worsening the neurologic function, can aggravate and promote the development of cerebral stroke, and theoretical basis and clinical foundation are provided for researching a new target and a new strategy of preventing, alleviating and / or treating cerebral stroke diseases.

The invention discloses tissue engineering neural tissue and a constructing method thereof, and belongs to the technical field of tissue engineering. Silk fibroin and collagen composite materials areadopted, primary cortical neurons are adopted as seed cells for three-dimensional culture, and tissue engineering neural tissue is formed. The operation steps are simple, and can be easily executed repeatedly, and no special technology or equipment requirement is met. The neural tissue constructed under the system generates a neural network with abundant network connection. The mechanical performance of the adopted silk fibroin is suitable for neural cell inoculation and culture, and the elasticity modulus of the neural tissue is close to that of rat brain tissue.

The invention discloses the application of an exogenous recombinant protein Reelin in the preparation of a drug for treating cerebral hemorrhage, belonging to the technical field of biomedicine. The invention discloses the time course change process of pyroptosis in striatum and cortex tissue after cerebral hemorrhage; the distribution of pyroptosis in different cell types in striatum and cortex tissue after cerebral hemorrhage; proves that Reelin improves striatum after cerebral hemorrhage It is proved that Reelin can reduce the pyroptosis of striatum and cortical neurons after cerebral hemorrhage; the present invention provides a basis for using Reelin as a new type of drug for the treatment of cerebral hemorrhage.

The invention belongs to the field of life science / medical technology, and discloses a non-therapeutic perceptual training method for inducing the plasticity of the auditory cortex, which includes a training device, which is located in a sound-proof shielding box, including a controller, a sound generator, Loudspeaker, food feeder, infrared nose detector and lighting lamp. The invention also discloses the application of the training device in induction of auditory cortical plasticity and perception training. The invention has the characteristics of non-invasiveness and broad spectrum, improves the frequency selectivity of auditory cortex neurons, and has wide application prospects.

The invention provides the application of extracellular vesicles derived from mesenchymal stem cells in cerebral ischemia-reperfusion injury. The present invention discovers and confirms that extracellular vesicles (MSCs-EVs) derived from mesenchymal stem cells can treat brain dysfunction and neuroprotection through neurogenesis and angiogenesis after stroke. The results of the study showed that MSCs-EVs could significantly alleviate the neurological deficit at 24h and 48h after MCAO in rats, reduce the volume of cerebral infarction and brain water content, improve the pathological damage of the cortex of the brain tissue, and attenuate the apoptosis of cortical neurons and significantly up-regulate p‑AMPK, while p‑JAK2, p‑STAT3 and p‑NF‑κB were downregulated. The present invention provides essential support for the use of MSCs‑EVs as a potential therapeutic strategy for MCAO treatment.

The present invention relates to glycolic acid or a pharmaceutically acceptable salt or ester thereof for use in the treatment or prevention of ischemic damage. In a preferred embodiment the present invention relates to a method for decreasing cell death caused by an ischemic insult comprising contacting glycolic acid or a pharmaceutically acceptable salt or ester thereof with hypoxic tissue, in particular cortical neurons or myocardial tissue.

A method is disclosed for predicting the stimulation effect of cortical neurons in response to extracellular electrical stimulation. The method comprising the steps of defining an electrode configuration, defining a reconstructed neuronal cell type, wherein the reconstructed neuronal cell is characteristic of the physical and electrical properties of a neuronal cell, computing an electric field potential at the reconstructed neuronal cell, computing an effective transmembrane current of an arborization of the reconstructed neuronal cell, and determining a probability of activation of the reconstructed neuronal cell. A method for inducing an electrical stimulation effect on a cortical column is also disclosed. In an embodiment, the predicted network response of a cortical column is used to configure one or more electrodes to induce cortical stimulation.